Currently, the anti‐Tau immunotherapies were suggested as potential interventions in AD, while most of the antibodies targeting Tau proteins failed in the clinical trials (Congdon et al., 2023; Monteiro et al., 2023), suggesting that the other strategies should also be considered for the treatment of Tau pathology. Here, MAPT is linked to Alzheimer disease.